How to access Hemgenix from the UAE, the named-patient coordination pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
An Emirati adult living with moderately severe to severe Hemophilia B, recurrent bleeds despite routine factor IX prophylaxis, may be evaluated by their treating haematologist for Hemgenix (etranacogene dezaparvovec). Hemgenix is FDA-approved, developed by CSL Behring and uniQure, and is a one-time intravenous adeno-associated virus (AAV5) gene therapy that delivers a functional factor IX transgene to the liver. Because Hemgenix is a single-infusion gene therapy with strict eligibility gating and a multi-year monitoring commitment, access for UAE patients involves cross-border referral to a gene-therapy-qualified treatment centre rather than a routine drug import.
This guide explains the legal and operational pathway, the eligibility gating, what your haematologist needs to coordinate, indicative timing and cost bands, and where Reserve Meds fits in.
The clinical situation
Hemgenix is delivered as a single IV infusion over one to two hours at a qualified gene-therapy centre. Eligibility is tightly gated: patients are screened for pre-existing neutralising antibodies against the AAV5 capsid (AAV5-negative titre is typically required), liver health (ALT/AST within bounds, no active HBV or HCV, no advanced fibrosis on elastography), and a factor-IX-inhibitor-free history. Post-infusion, patients are monitored closely for transaminitis and generally receive a tapering oral corticosteroid course if liver enzyme rises occur. Long-term surveillance for factor IX activity, liver function, and AAV-related safety signals continues for at least five years per manufacturer and regulatory guidance.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Is Hemgenix legally accessible for UAE patients?
Hemgenix cannot be "imported" as a conventional drug for local infusion, it is a single-vial one-time product requiring administration at a gene-therapy-qualified centre with the infrastructure to manage pre-infusion screening, infusion monitoring, and the multi-year follow-up protocol. Access for UAE patients typically follows cross-border referral within the UAE Ministry of Health and Prevention (MoHAP) and Ministry of Health medical-referral framework:
Pattern A, Cross-border referral to an authorised gene-therapy centre. The patient travels to a qualified international centre (in the US, Europe, or a select Middle-East tertiary centre operating under the manufacturer's qualified-treatment-centre model) for eligibility workup, infusion, and early post-infusion monitoring. Long-term surveillance is then handed back to the UAE haematologist.
Pattern B, Hybrid coordination with an Emirati tertiary centre. Where an Emirati centre participates in CSL Behring's qualified-treatment-centre network, portions of screening and long-term follow-up may be localised.
The MoHAP and MoH medical-referral frameworks support both patterns, with documentation covering medical necessity, treatment-centre identification, and the return-to-home surveillance plan.
How the pathway works, step by step
- Consultation with your haematologist. Bleed history, prior factor IX regimen, inhibitor history, and liver status are reviewed.
- Eligibility workup. AAV5 capsid antibody titre, factor IX inhibitor assay, hepatic panel with elastography, and hepatitis serology.
- Treatment-centre identification. Reserve Meds coordinates referral to a qualified gene-therapy centre.
- MoHAP / MoH medical-referral dossier. Filed by your physician with supporting clinical rationale.
- Cross-border travel and infusion. Single IV infusion at the qualified centre; inpatient observation and early outpatient monitoring.
- Handover to the UAE haematology team. Structured multi-year surveillance plan covering factor IX activity, LFTs, and AAV safety parameters.
What documentation your physician needs
Your physician will typically need to provide:
- Clinical rationale letter with diagnosis, bleed phenotype, prior prophylaxis, inhibitor history, and Hemgenix as the indicated therapy
- Verification of their UAE medical licence (SCFHS / MOH)
- AAV5 capsid antibody, factor IX inhibitor, and hepatic workup results
- Identification of the qualified treatment centre and the referral plan
- Long-term surveillance plan for return to the UAE
Reserve Meds provides a coordination kit bundling the templates MoHAP reviewers and qualified treatment centres expect to see for cross-border gene-therapy referrals.
Costs and timing
Hemgenix's US list price for the one-time product is indicatively around USD 3.5 million; total cost of care, including pre-infusion workup, infusion-day services, inpatient/outpatient monitoring, and travel for a family caregiver, runs materially higher when delivered at a US qualified centre. Reserve Meds issues a transparent all-in quote at intake. Because this is a one-time therapy rather than a recurring prophylaxis spend, families often work with their haematologist and financial advisor to model the cost against a lifetime of factor IX prophylaxis.
Indicative timing from intake to infusion typically runs 10-20 weeks, driven by eligibility workup, treatment-centre calendar, and travel coordination. Early post-infusion monitoring typically requires several weeks at or near the qualified centre.
If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.
A culturally-aware note: gene-therapy journeys typically require a family caregiver throughout the extended stay; our coordination includes caregiver travel, prayer-space orientation, and halal-dining support at partnering centres.
Reserve Meds's role
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine and gene therapy. For Hemgenix specifically, we provide:
- Treatment-centre referral. Coordination with authorised Hemgenix qualified-treatment centres.
- Documentation. Cross-border referral and MoHAP/MoH named-patient package.
- Logistics. Patient and caregiver travel, accommodation, and post-infusion return-home planning.
- Concierge case lead. A named point of contact throughout the gene-therapy journey.
What we do not do: we are not the prescriber, we do not practise medicine, we do not manufacture the product, and we are not the treatment centre. All clinical decisions remain with your treating haematologist and the qualified centre.
Frequently asked
Is this legal in the UAE? Yes, when executed through the MoHAP and MoH medical-referral framework with a qualified treatment centre. See our trust and compliance page.
What if my AAV5 antibody titre is positive? Pre-existing AAV5 neutralising antibodies above the manufacturer's threshold typically exclude a patient from Hemgenix. Your haematologist will review options with you.
Will I still need factor IX prophylaxis afterward? Clinical trial data show many patients experience durable factor IX expression with reduced or discontinued prophylaxis. Your haematologist manages the taper decision based on serial factor IX activity measurements.
What about long-term safety? Multi-year surveillance is a core part of the protocol, including liver function monitoring. Your haematology team will explain the full profile.
Will MoH coverage apply? Some UAE patients receive partial coverage for complex international referrals; we supply documentation for submission but do not process public-payer claims directly.
Next step
Composite case examples. This content is for general information and does not constitute medical advice.
Clinical & regulatory review: Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last medically reviewed: 2026-04-23.
Regulatory status of Hemgenix in United Arab Emirates, 2026
Hemgenix (etranacogene dezaparvovec-drlb) is not currently held on the locally registered medicines list of the Ministry of Health and Prevention (MOHAP). The product is approved by the US Food and Drug Administration per the labelled indication of haemophilia B in adults who currently use factor IX prophylaxis or have current or historical life-threatening haemorrhage or repeated serious spontaneous bleeding episodes (see the FDA label at accessdata.fda.gov). The European Medicines Agency holds a parallel marketing authorisation where applicable (see the EMA EPAR at ema.europa.eu).
Because Hemgenix is not on the MOHAP locally registered list, access for a United Arab Emirates-based patient runs through the named-patient and personal-import framework that the MOHAP maintains for reference-authority-approved medicines that are not held locally. The official MOHAP portal is at mohap.gov.ae. The qualifying conditions are well established: the medicine is approved by a recognised reference authority (FDA or EMA qualifies); no locally available alternative is clinically equivalent for the specific patient indication; the treating physician of record takes documented clinical responsibility; and chain of custody is preserved end to end from the US source through international transit to the named dispensing facility.
The named-patient and personal-import pathway is the routine framework. For a complex cell or gene therapy that requires a US-certified treatment center, the practical route is patient travel to that certified center rather than import into United Arab Emirates; see Block 2 below for the operational shape on that case type.
Tertiary centers and clinical coordination in United Arab Emirates
The United Arab Emirates tertiary referral network for a Hemgenix case is concentrated at Cleveland Clinic Abu Dhabi (CCAD), Sheikh Shakhbout Medical City (SSMC), and Tawam Hospital. These centers carry the haematology, oncology, paediatric subspecialty, or rare-disease specialist staffing and the institutional pharmacy and import-license operations that the named-patient pathway requires. For cellular and gene therapies that require leukapheresis collection, AAV infusion, or post-treatment monitoring of a complexity beyond what a community centre is configured for, the case is routinely referred to one of these tertiary centers from the outset.
For cell and gene therapies specifically, the practical access pathway runs through patient travel to a US-certified treatment center (Casgevy authorised treatment centers, Yescarta certified centers, Abecma certified centers, Zolgensma certified centers, Elevidys treatment centers, Hemgenix treatment centers, and so on) rather than import of the cellular or AAV product into United Arab Emirates. The tertiary United Arab Emirates centers handle the upstream referral package assembly (clinical summary, pathology, imaging, organ function panel, infectious disease screen, performance status), the US-side coordination, and the long-term follow-up after the patient returns home. Reserve Meds coordinates the cross-border arc between the United Arab Emirates tertiary team and the US treatment center, including travel and accommodation logistics, financial clearance, and post-treatment data flow.
For oral kinase inhibitors and antibody therapies that can be administered in United Arab Emirates once imported, the tertiary centres dispense and monitor under their institutional pharmacy operations. Reserve Meds handles US-side sourcing under Drug Supply Chain Security Act (DSCSA) chain-of-custody documentation, international shipment to the named dispensing facility, and re-supply cadence aligned to the dosing schedule.
United Arab Emirates pricing reference and payer posture, 2026
Reserve Meds publishes a drug-only US cash-pay reference range at intake and issues a delivered, itemised quote within 24 hours once your treating physician's documentation is in. As an illustrative composite case in the 2026 reference band, the US cash-pay drug-only range for Hemgenix sits at approximately USD 3,450,000 to USD 3,500,000 per one-time AAV5 gene therapy infusion (US wholesale acquisition cost). In AED terms at the 2026 reference rate of 1 USD = 3.670 AED, that translates to a drug-only band of approximately AED 12,661,500 to AED 12,845,000.
Logistics, international shipment, chain-of-custody documentation, cold-chain handling where applicable, US treatment center facility and physician fees where applicable (for cellular and gene therapies, the facility cost commonly equals or exceeds the product cost), Reserve Meds concierge coordination, and any patient and caregiver travel and accommodation are itemised separately. For a cell or gene therapy case the total course cost in 2026 commonly lands at 1.5x to 2.5x the drug-only band once US treatment center fees, lymphodepletion or pre-infusion conditioning, inpatient monitoring, complication management, and family travel and accommodation are added in.
Payer posture in United Arab Emirates is overwhelmingly cash-pay for named-patient imports and cross-border CAR-T cases. Public coverage (DHA Dubai Health Authority and DoH Abu Dhabi insurance schemes) generally does not extend to non-locally-registered specialty cases. Private health insurance plans review case-by-case on a pre-authorisation basis when the documentation package is strong, but cash-pay should be assumed as the default at intake.
Access barriers and how Reserve Meds clears them
The five access barriers we see most often for a Hemgenix case in United Arab Emirates are: (1) Regulatory documentation complexity. The MOHAP named-patient and personal-import application package requires a specific bundle (physician clinical rationale letter, prescription, patient identifier, product strength and quantity, chain-of-custody plan, evidence of reference-authority approval, and confirmation that no locally available alternative is clinically equivalent for the patient). Reserve Meds provides physician-facing templates that match the format MOHAP reviewers expect. (2) US-side sourcing and DSCSA chain-of-custody. We coordinate with our US-licensed specialty wholesale partners to secure Hemgenix from authorised distribution under the US Drug Supply Chain Security Act, logging every transfer point through to international shipment.
(3) For cell and gene therapies, the US-certified treatment center qualification gate. Casgevy, Yescarta, Carvykti, Abecma, Zolgensma, Elevidys, Hemgenix, and Luxturna can only be administered at a manufacturer-certified treatment center. Reserve Meds maintains the referral arcs to the appropriate US-certified centers and handles the referral package routing, financial clearance, and the multi-week stay coordination. (4) Family logistics. Patient and caregiver travel, accommodation near the treatment center, in-US transport, translator support where needed, and post-treatment data flow back to the treating United Arab Emirates physician are coordinated as a single arc. (5) Insurance and payer posture. Cash-pay is the default. Where private insurance review is contemplated, we supply documentation for the family's submission but we do not bill insurers and we do not adjudicate insurance disputes.
Drug-specific clinical context for Hemgenix: the labelled indication is haemophilia B in adults who currently use factor IX prophylaxis or have current or historical life-threatening haemorrhage or repeated serious spontaneous bleeding episodes. The relevant clinical-practice guideline body is World Federation of Hemophilia (WFH) treatment guidelines at www.wfh.org. Your treating physician of record makes the clinical decision; Reserve Meds is the coordination layer that clears the operational and regulatory barriers between the prescription and the delivered course.
Recent regulatory and access news for Hemgenix in United Arab Emirates, 2026
The Ministry of Health and Prevention (MOHAP) portal at mohap.gov.ae has not posted a Hemgenix-specific listing on the publicly searchable locally registered medicines list at mohap.gov.ae/en/services/medicine-search as of 2026-06-04. The FDA Drug Safety Communications feed at fda.gov drug-safety-communications and the FDA Drug Shortages list at accessdata.fda.gov drugshortages have not registered a Hemgenix-specific safety advisory or shortage signal over the most recent 12-month window. The FDA labelled indication remains haemophilia B in adults who currently use factor IX prophylaxis or have current or historical life-threatening haemorrhage or repeated serious spontaneous bleeding episodes (see the current label at accessdata.fda.gov). CSL Behring (licensed from uniQure) continues commercial supply per the FDA-labelled indication and the EMA marketing authorisation. The World Federation of Hemophilia (WFH) treatment guidelines guidance at www.wfh.org remains the relevant clinical-practice reference. Reserve Meds refreshes this snapshot per case at intake; the snapshot date governs.